Dai, Ming-ShenMing-ShenDaiChao, Ta-ChungTa-ChungChaoChiu, Chang-FangChang-FangChiuYEN-SHEN LUShiah, Her-ShyongHer-ShyongShiahJackson, Christopher G C AChristopher G C AJacksonHung, NoelynNoelynHungZhi, JianguoJianguoZhiCutler, David LDavid LCutlerKwan, RudolfRudolfKwanKramer, DouglasDouglasKramerChan, Wing-KaiWing-KaiChanQin, AlbertAlbertQinTseng, Kuan-ChiaoKuan-ChiaoTsengHung, Cheung TakCheung TakHungChao, Tsu-YiTsu-YiChao2023-11-082023-11-0820231758-8340https://scholars.lib.ntu.edu.tw/handle/123456789/636972Paclitaxel is widely used for the treatment of metastatic breast cancer (MBC). However, it has a low oral bioavailability due to gut extrusion caused by P-glycoprotein (P-gp). Oral paclitaxel (oPAC) may be more convenient, less resource-intensive, and more tolerable than its intravenous form. Encequidar (E) is a first-in-class, minimally absorbed, gut-specific oral P-gp inhibitor that facilitates the oral absorption of paclitaxel.enHM30181A; P-gp inhibitor; efficacy; encequidar; oral paclitaxel; pharmacokinetics; safety[SDGs]SDG3journal article10.1177/17588359231183680374926332-s2.0-85165557588https://api.elsevier.com/content/abstract/scopus_id/85165557588